CoChat

Cerebrovascular insulin receptors are defective in Alzheimer’s disease

Open access
Leclerc, Manon, Bourassa, Philippe, Tremblay, Cyntia, Caron, Vicky, Sugère, Camille, Emond, Vincent, Bennett, David A, Calon, Frédéric · 2023 · Brain
Cited by 108

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Abstract

Central response to insulin is suspected to be defective in Alzheimer’s disease. As most insulin is secreted in the bloodstream by the pancreas, its capacity to regulate brain functions must, at least partly, be mediated through the cerebral vasculature. However, how insulin interacts with the blood–brain barrier and whether alterations of this interaction could contribute to Alzheimer’s disease pathophysiology both remain poorly defined. Here, we show that human and murine cerebral insulin receptors (INSRs), particularly the long isoform INSRα-B, are concentrated in microvessels rather than in the parenchyma. Vascular concentrations of INSRα-B were lower in the parietal cortex of subjects diagnosed with Alzheimer’s disease, positively correlating with cognitive scores, leading to a shift towards a higher INSRα-A/B ratio, consistent with cerebrovascular insulin resistance in the Alzheimer’s disease brain. Vascular INSRα was inversely correlated with amyloid-β plaques and β-site APP cleaving enzyme 1, but positively correlated with insulin-degrading enzyme, neprilysin and P-glycoprotein. Using brain cerebral intracarotid perfusion, we found that the transport rate of insulin across the blood–brain barrier remained very low (<0.03 µl/g·s) and was not inhibited by an insulin receptor antagonist. However, intracarotid perfusion of insulin induced the phosphorylation of INSRβ that was restricted to microvessels. Such an activation of vascular insulin receptor was blunted in 3xTg-AD mice, suggesting that Alzheimer’s disease neuropathology induces insulin resistance at the level of the blood–brain barrier. Overall, the present data in post-mortem Alzheimer’s disease brains and an animal model of Alzheimer’s disease indicate that defects in the insulin receptor localized at the blood–brain barrier strongly contribute to brain insulin resistance in Alzheimer’s disease, in association with β-amyloid pathology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awac309

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 111

  1. Lewis, 2021, The discovery of insulin revisited: Lessons for the modern era, J Clin Invest, 131, 10.1172/JCI142239 · DOI
  2. Polyzos, 2021, Diabetes mellitus: 100 years since the discovery of insulin, Metabolism, 118, 154737, 10.1016/j.metabol.2021.154737 · DOI
  3. Moran, 2019, Diabetes therapies for dementia, Curr Neurol Neurosci Rep, 19, 58, 10.1007/s11910-019-0973-4 · DOI
  4. Frank, 1981, A direct in vitro demonstration of insulin binding to isolated brain microvessels, Diabetes, 30, 757, 10.2337/diab.30.9.757 · DOI · Paper page
  5. Haskell, 1985, Identification of the insulin receptor of cerebral microvessels, Am J Physiol Endocrinol Metab, 248, E115, 10.1152/ajpendo.1985.248.1.E115 · DOI
  6. Vicent, 2003, The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance, J Clin Invest, 111, 1373, 10.1172/JCI15211 · DOI · Paper page
  7. Belfiore, 2017, Insulin receptor isoforms in physiology and disease: An updated view, Endocr Rev, 38, 379, 10.1210/er.2017-00073 · DOI · Paper page
  8. Mosthaf, 1990, Functionally distinct insulin receptors generated by tissue-specific alternative splicing, Embo J, 9, 2409, 10.1002/j.1460-2075.1990.tb07416.x · DOI · Paper page
  9. Yamaguchi, 1993, Ligand-binding properties of the two isoforms of the human insulin receptor, Endocrinology, 132, 1132, 10.1210/endo.132.3.8440175 · doi:10.1210/endo.132.3.8440175
  10. Kellerer, 1992, Distinct alpha-subunit structures of human insulin receptor A and B variants determine differences in tyrosine kinase activities, Biochemistry, 31, 4588, 10.1021/bi00134a008 · DOI
  11. De Felice, 2013, Alzheimer’s disease and insulin resistance: Translating basic science into clinical applications, J Clin Invest, 123, 531, 10.1172/JCI64595 · DOI · Paper page
  12. Baglietto-Vargas, 2016, Diabetes and Alzheimer's disease crosstalk, Neurosci Biobehav Rev, 64, 272, 10.1016/j.neubiorev.2016.03.005 · DOI · Paper page
  13. de la Monte, 2019, The full spectrum of Alzheimer's disease is rooted in metabolic derangements that drive type 3 diabetes, Adv Exp Med Biol, 1128, 45, 10.1007/978-981-13-3540-2_4 · DOI · Paper page
  14. Stanley, 2016, The effects of peripheral and central high insulin on brain insulin signaling and amyloid-beta in young and old APP/PS1 mice, J Neurosci, 36, 11704, 10.1523/JNEUROSCI.2119-16.2016 · DOI · Paper page
  15. Arvanitakis, 2020, Brain insulin signaling, Alzheimer disease pathology, and cognitive function, Ann Neurol, 88, 513, 10.1002/ana.25826 · DOI · Paper page
  16. Vandal, 2014, Insulin reverses the high-fat diet-induced increase in brain Abeta and improves memory in an animal model of Alzheimer disease, Diabetes, 63, 4291, 10.2337/db14-0375 · DOI · Paper page
  17. Sanguinetti, 2019, Combined effect of fatty diet and cognitive decline on brain metabolism, food intake, body weight, and counteraction by intranasal insulin therapy in 3xTg mice, Front Cell Neurosci, 13, 188, 10.3389/fncel.2019.00188 · DOI
  18. Kellar, 2021, Intranasal insulin reduces white matter hyperintensity progression in association with improvements in cognition and CSF biomarker profiles in mild cognitive impairment and Alzheimer's disease, J Prev Alzheimers Dis, 8, 240
  19. Gwizdala, 2021, Placebo controlled phase II clinical trial: Safety and efficacy of combining intranasal insulin & acute exercise, Metab Brain Dis, 36, 1289, 10.1007/s11011-021-00727-2 · DOI
  20. Rosenbloom, 2021, A phase II, single-center, randomized, double-blind, placebo-controlled study of the safety and therapeutic efficacy of intranasal glulisine in amnestic mild cognitive impairment and probable mild Alzheimer's disease, Drugs Aging, 38, 407, 10.1007/s40266-021-00845-7 · DOI
  21. Hölscher, 2022, Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders, Br J Pharmacol, 179, 695, 10.1111/bph.15508 · DOI · Paper page
  22. Cummings, 6 2022, Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease, Eur J Neurosci, 10.1111/ejn.15619 · DOI · Paper page
  23. Lourenco, 2015, Neuronal stress signaling and eIF2alpha phosphorylation as molecular links between Alzheimer's disease and diabetes, Prog Neurobiol, 129, 37, 10.1016/j.pneurobio.2015.03.003 · DOI
  24. Frazier, 2020, Molecular elevation of insulin receptor signaling improves memory recall in aged Fischer 344 rats, Aging Cell, 19, e13220, 10.1111/acel.13220 · DOI
  25. Moss, 1990, Location of phosphotyrosine-containing proteins by immunocytochemistry in the rat forebrain corresponds to the distribution of the insulin receptor, Proc Natl Acad Sci USA, 87, 4453, 10.1073/pnas.87.12.4453 · DOI · Paper page
  26. Unger, 1989, Distribution of insulin receptor-like immunoreactivity in the rat forebrain, Neuroscience, 31, 143, 10.1016/0306-4522(89)90036-5 · DOI · Paper page
  27. Doré, 1997, Distribution and levels of [125I]IGF-I, [125I]IGF-II and [125I]insulin receptor binding sites in the hippocampus of aged memory-unimpaired and -impaired rats, Neuroscience, 80, 1033, 10.1016/S0306-4522(97)00154-1 · DOI
  28. Kar, 1993, Quantitative autoradiographic localization of [125I]insulin-like growth factor I, [125I]insulin-like growth factor II, and [125I]insulin receptor binding sites in developing and adult rat brain, J Comp Neurol, 333, 375, 10.1002/cne.903330306 · DOI · Paper page
  29. Baskin, 1986, Quantitative autoradiographic evidence for insulin receptors in the choroid plexus of the rat brain, Diabetes, 35, 246, 10.2337/diab.35.2.246 · DOI · Paper page
  30. Zhang, 2020, Differential expression of receptors mediating receptor-mediated transcytosis (RMT) in brain microvessels, brain parenchyma and peripheral tissues of the mouse and the human, Fluids Barriers CNS, 17, 47, 10.1186/s12987-020-00209-0 · DOI · Paper page
  31. Gali, 2019, Amyloid-beta impairs insulin signaling by accelerating autophagy-lysosomal degradation of LRP-1 and IR-β in blood-brain barrier endothelial cells in vitro and in 3XTg-AD mice, Mol Cell Neurosci, 99, 103390, 10.1016/j.mcn.2019.103390 · DOI · Paper page
  32. Rhea, 2019, Role of the blood-brain barrier in central nervous system insulin resistance, Front Neurosci, 13, 521, 10.3389/fnins.2019.00521 · DOI · Paper page
  33. Duffy, 1987, Blood-brain barrier transcytosis of insulin in developing rabbits, Brain Res, 420, 32, 10.1016/0006-8993(87)90236-8 · DOI · Paper page
  34. Banks, 1998, Differential permeability of the blood-brain barrier to two pancreatic peptides: Insulin and amylin, Peptides, 19, 883, 10.1016/S0196-9781(98)00018-7 · DOI · Paper page
  35. Gray, 2017, Unravelling the regulation of insulin transport across the brain endothelial cell, Diabetologia, 60, 1512, 10.1007/s00125-017-4285-4 · DOI · Paper page
  36. Woods, 2003, Insulin and the blood-brain barrier, Curr Pharm Des, 9, 795, 10.2174/1381612033455323 · DOI · Paper page
  37. Rhea, 2018, Insulin transport across the blood-brain barrier can occur independently of the insulin receptor, J Physiol, 596, 4753, 10.1113/JP276149 · DOI · Paper page
  38. Hersom, 2018, The insulin receptor is expressed and functional in cultured blood-brain barrier endothelial cells but does not mediate insulin entry from blood to brain, Am J Physiol Endocrinol Metab, 315, E531, 10.1152/ajpendo.00350.2016 · DOI · Paper page
  39. Gray, 2018, Insulin transport into the brain, Am J Physiol Cell Physiol, 315, C125, 10.1152/ajpcell.00240.2017 · DOI
  40. Bourassa, 2020, Brain mural cell loss in the parietal cortex in Alzheimer's disease correlates with cognitive decline and TDP-43 pathology, Neuropathol Appl Neurobiol, 46, 458, 10.1111/nan.12599 · DOI
  41. Bourassa, 2019, Beta-amyloid pathology in human brain microvessel extracts from the parietal cortex: Relation with cerebral amyloid angiopathy and Alzheimer's disease, Acta Neuropathol, 137, 801, 10.1007/s00401-019-01967-4 · DOI
  42. Bennett, 2006, Decision rules guiding the clinical diagnosis of Alzheimer's disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study, Neuroepidemiology, 27, 169, 10.1159/000096129 · DOI · Paper page
  43. Bennett, 2002, Natural history of mild cognitive impairment in older persons, Neurology, 59, 198, 10.1212/WNL.59.2.198 · DOI · Paper page
  44. Arvanitakis, 2008, Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology, Neurology, 70, 2219, 10.1212/01.wnl.0000313813.48505.86 · DOI · Paper page
  45. Arvanitakis, 2008, Statins, incident Alzheimer disease, change in cognitive function, and neuropathology, Neurology, 70, 1795, 10.1212/01.wnl.0000288181.00826.63 · DOI · Paper page
  46. Mirra, 1991, The consortium to establish a registry for Alzheimer's disease (CERAD). part II. Standardization of the neuropathologic assessment of Alzheimer's disease, Neurology, 41, 479, 10.1212/WNL.41.4.479 · DOI · Paper page
  47. Tremblay, 2017, Association of neuropathological markers in the parietal cortex with antemortem cognitive function in persons with mild cognitive impairment and Alzheimer disease, J Neuropathol Exp Neurol, 76, 70, 10.1093/jnen/nlw109 · DOI
  48. Tremblay, 2007, Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer's disease, J Alzheimers Dis, 12, 377, 10.3233/JAD-2007-12411 · DOI · Paper page
  49. Vandal, 2016, Impaired thermoregulation and beneficial effects of thermoneutrality in the 3xTg-AD model of Alzheimer's disease, Neurobiol Aging, 43, 47, 10.1016/j.neurobiolaging.2016.03.024 · DOI
  50. Vandal, 2015, Age-dependent impairment of glucose tolerance in the 3xTg-AD mouse model of Alzheimer's disease, FASEB J, 29, 4273, 10.1096/fj.14-268482 · DOI · Paper page
  51. Do, 2015, Age-dependent regulation of the blood-brain barrier influx/efflux equilibrium of amyloid-beta peptide in a mouse model of Alzheimer's disease (3xTg-AD), J Alzheimers Dis, 49, 287, 10.3233/JAD-150350 · DOI · Paper page
  52. Stargardt, 2013, Reduced amyloid-β degradation in early Alzheimer's disease but not in the APPswePS1dE9 and 3xTg-AD mouse models, Aging Cell, 12, 499, 10.1111/acel.12074 · DOI · Paper page
  53. Bosoi, 2021, High-fat diet modulates hepatic amyloid β and cerebrosterol metabolism in the triple transgenic mouse model of Alzheimer's disease, Hepatol Commun, 5, 446, 10.1002/hep4.1609 · DOI
  54. Barron, 2013, Sex-specific effects of high fat diet on indices of metabolic syndrome in 3xTg-AD mice: Implications for Alzheimer's disease, PLoS ONE, 8, e78554, 10.1371/journal.pone.0078554 · DOI · Paper page
  55. Robison, 2020, Role of sex and high-fat diet in metabolic and hypothalamic disturbances in the 3xTg-AD mouse model of Alzheimer's disease, J Neuroinflammation, 17, 285, 10.1186/s12974-020-01956-5 · DOI · Paper page
  56. Chen, 2014, Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Abeta level and microglia activation in the brains of 3xTg-AD mice, Exp Neurol, 261, 610, 10.1016/j.expneurol.2014.06.004 · DOI
  57. Traversy, 2017, Altered cerebral insulin response in transgenic mice expressing the epsilon-4 allele of the human apolipoprotein E gene, Psychoneuroendocrinology, 77, 203, 10.1016/j.psyneuen.2016.11.028 · DOI · Paper page
  58. Do, 2014, Altered cerebral vascular volumes and solute transport at the blood-brain barriers of two transgenic mouse models of Alzheimer's disease, Neuropharmacology, 81, 311, 10.1016/j.neuropharm.2014.02.010 · DOI · Paper page
  59. Escribano, 2009, Beta-cell hyperplasia induced by hepatic insulin resistance: Role of a liver-pancreas endocrine axis through insulin receptor A isoform, Diabetes, 58, 820, 10.2337/db08-0551 · DOI
  60. Kaminska, 2014, Adipose tissue INSR splicing in humans associates with fasting insulin level and is regulated by weight loss, Diabetologia, 57, 347, 10.1007/s00125-013-3097-4 · DOI
  61. Besic, 2015, Aberrant liver insulin receptor isoform A expression normalises with remission of type 2 diabetes after gastric bypass surgery, PLoS ONE, 10, e0119270, 10.1371/journal.pone.0119270 · DOI
  62. Chettouh, 2013, Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors, Cancer Res, 73, 3974, 10.1158/0008-5472.CAN-12-3824 · DOI · Paper page
  63. Flatt, 1981, Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice, Diabetologia, 20, 573, 10.1007/BF00252768 · DOI · Paper page
  64. Ahrén, 1997, Regulation of plasma leptin in mice: Influence of age, high-fat diet, and fasting, Am J Physiol, 273, R113
  65. Williams, 2018, Insulin exits skeletal muscle capillaries by fluid-phase transport, J Clin Invest, 128, 699, 10.1172/JCI94053 · DOI · Paper page
  66. Meakin, 2018, The beta secretase BACE1 regulates the expression of insulin receptor in the liver, Nat Commun, 9, 1306, 10.1038/s41467-018-03755-2 · DOI · Paper page
  67. Bao, 2021, Increased beta-site APP cleaving enzyme 1-mediated insulin receptor cleavage in type 2 diabetes mellitus with cognitive impairment, Alzheimers Dement, 17, 1097, 10.1002/alz.12276 · DOI · Paper page
  68. Baskin, 1983, Regional concentrations of insulin in the rat brain, Endocrinology, 112, 898, 10.1210/endo-112-3-898 · DOI · Paper page
  69. Cai, 2018, Insulin regulates astrocyte gliotransmission and modulates behavior, J Clin Invest, 128, 2914, 10.1172/JCI99366 · DOI · Paper page
  70. García-Cáceres, 2016, Astrocytic insulin signaling couples brain glucose uptake with nutrient availability, Cell, 166, 867, 10.1016/j.cell.2016.07.028 · DOI · Paper page
  71. Schubert, 2004, Role for neuronal insulin resistance in neurodegenerative diseases, Proc Natl Acad Sci USA, 101, 3100, 10.1073/pnas.0308724101 · DOI · Paper page
  72. Gralle, 2021, Spatial dynamics of the insulin receptor in living neurons, J Neurochem, 156, 88, 10.1111/jnc.14950 · DOI
  73. Jin, 2011, Insulin reduces neuronal excitability by turning on GABA(A) channels that generate tonic current, PLoS ONE, 6, e16188, 10.1371/journal.pone.0016188 · DOI · Paper page
  74. Sartorius, 2015, The brain response to peripheral insulin declines with age: A contribution of the blood-brain barrier?, PLoS ONE, 10, e0126804, 10.1371/journal.pone.0126804 · DOI · Paper page
  75. Hooshmand, 2019, Serum insulin and cognitive performance in older adults: A longitudinal study, Am J Med, 132, 367, 10.1016/j.amjmed.2018.11.013 · DOI
  76. Li, 2015, Age and its association with low insulin and high amyloid-β peptides in blood, J Alzheimers Dis, 49, 129, 10.3233/JAD-150428 · DOI
  77. Zhao, 2004, Insulin and the insulin receptor in experimental models of learning and memory, Eur J Pharmacol, 490, 71, 10.1016/j.ejphar.2004.02.045 · DOI · Paper page
  78. Banks, 1997, Effect of diabetes mellitus on the permeability of the blood-brain barrier to insulin, Peptides, 18, 1577, 10.1016/S0196-9781(97)00238-6 · DOI
  79. Urayama, 2008, Starvation and triglycerides reverse the obesity-induced impairment of insulin transport at the blood-brain barrier, Endocrinology, 149, 3592, 10.1210/en.2008-0008 · DOI · Paper page
  80. Banks, 2000, Permeability of the blood-brain barrier to albumin and insulin in the young and aged SAMP8 mouse, J Gerontol A Biol Sci Med Sci, 55, B601, 10.1093/gerona/55.12.B601 · DOI · Paper page
  81. Vella, 2018, Insulin receptor isoforms in cancer, Int J Mol Sci, 19, 3615, 10.3390/ijms19113615 · DOI
  82. Escribano, 2017, The role of insulin receptor isoforms in diabetes and its metabolic and vascular complications, J Diabetes Res, 2017, 1, 10.1155/2017/1403206 · DOI
  83. Scalia, 2020, Isoform- and paralog-switching in IR-signaling: When diabetes opens the gates to cancer, Biomolecules, 10, 1617, 10.3390/biom10121617 · DOI
  84. Pandini, 2002, Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved, J Biol Chem, 277, 39684, 10.1074/jbc.M202766200 · DOI · Paper page
  85. Benyoucef, 2007, Characterization of insulin/IGF hybrid receptors: Contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation, Biochem J, 403, 603, 10.1042/BJ20061709 · DOI · Paper page
  86. Slaaby, 2006, Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant, J Biol Chem, 281, 25869, 10.1074/jbc.M605189200 · DOI · Paper page
  87. Arvanitakis, 2021, Brain insulin signaling and cerebrovascular disease in human postmortem brain, Acta Neuropathol Commun, 9, 71, 10.1186/s40478-021-01176-9 · DOI
  88. Velazquez, 2017, Central insulin dysregulation and energy dyshomeostasis in two mouse models of Alzheimer's disease, Neurobiol Aging, 58, 1, 10.1016/j.neurobiolaging.2017.06.003 · DOI · Paper page
  89. Kappeler, 2008, Brain IGF-1 receptors control mammalian growth and lifespan through a neuroendocrine mechanism, PLoS Biol, 6, e254, 10.1371/journal.pbio.0060254 · DOI · Paper page
  90. Torres-Aleman, 2007, Targeting insulin-like growth factor-1 to treat Alzheimer's disease, Expert Opin Ther Targets, 11, 1535, 10.1517/14728222.11.12.1535 · DOI · Paper page
  91. Gualco, 2009, IGF-IR in neuroprotection and brain tumors, Front Biosci (Landmark Ed), 14, 352, 10.2741/3249 · DOI
  92. Rosenzweig, 2020, The continuing evolution of insulin-like growth factor signaling, F1000Res, 9, 205, 10.12688/f1000research.22198.1 · DOI
  93. Denley, 2005, Molecular interactions of the IGF system, Cytokine Growth Factor Rev, 16, 421, 10.1016/j.cytogfr.2005.04.004 · DOI · Paper page
  94. Macauley, 2015, Hyperglycemia modulates extracellular amyloid-β concentrations and neuronal activity in vivo, J Clin Invest, 125, 2463, 10.1172/JCI79742 · DOI · Paper page
  95. Miners, 2006, Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy, J Neuropathol Exp Neurol, 65, 1012, 10.1097/01.jnen.0000240463.87886.9a · DOI · Paper page
  96. Farris, 2003, Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo, Proc Natl Acad Sci USA, 100, 4162, 10.1073/pnas.0230450100 · DOI · Paper page
  97. Kurochkin, 1994, Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme, FEBS Lett, 345, 33, 10.1016/0014-5793(94)00387-4 · DOI · Paper page
  98. Storck, 2022, The blood-brain barrier in Alzheimer's disease, Handb Exp Pharmacol
  99. Xie, 2002, Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor, J Neurosci, 22, RC221, 10.1523/JNEUROSCI.22-10-j0001.2002 · DOI · Paper page
  100. Stockley, 2007, The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain, Biochem Soc Trans, 35, 574, 10.1042/BST0350574 · DOI · Paper page
  101. Li, 2004, Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients, Proc Natl Acad Sci USA, 101, 3632, 10.1073/pnas.0205689101 · DOI · Paper page
  102. Fukumoto, 2002, Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease, Arch Neurol, 59, 1381, 10.1001/archneur.59.9.1381 · DOI · Paper page
  103. Kwart, 2019, A large panel of isogenic APP and PSEN1 mutant human iPSC neurons reveals shared endosomal abnormalities mediated by APP β-CTFs, not Aβ, Neuron, 104, 256, 10.1016/j.neuron.2019.07.010 · DOI · Paper page
  104. Chen, 2018, Reciprocal regulation of eNOS and caveolin-1 functions in endothelial cells, Mol Biol Cell, 29, 1190, 10.1091/mbc.E17-01-0049 · DOI
  105. Haddad, 2020, Role of caveolin-1 in diabetes and its complications, Oxid Med Cell Longev, 2020, 1, 10.1155/2020/9761539 · DOI
  106. Taylor, 2003, Curbing activation: Proprotein convertases in homeostasis and pathology, Faseb J, 17, 1215, 10.1096/fj.02-0831rev · DOI · Paper page
  107. Devraj, 2016, BACE-1 is expressed in the blood-brain barrier endothelium and is upregulated in a murine model of Alzheimer's disease, J Cereb Blood Flow Metab, 36, 1281, 10.1177/0271678X15606463 · DOI · Paper page
  108. Yuasa, 2016, Sequential cleavage of insulin receptor by calpain 2 and γ-secretase impairs insulin signalling, Diabetologia, 59, 2711, 10.1007/s00125-016-4102-5 · DOI
  109. Gaborit, 2021, The aminosterol claramine inhibits β-secretase 1-mediated insulin receptor cleavage, J Biol Chem, 297, 100818, 10.1016/j.jbc.2021.100818 · DOI
  110. Soluble Insulin Receptor Study Group, 2007, Soluble insulin receptor ectodomain is elevated in the plasma of patients with diabetes, Diabetes, 56, 2028, 10.2337/db07-0394 · DOI · Paper page
  111. Shen, 2018, Increased plasma beta-secretase 1 may predict conversion to Alzheimer's disease dementia in individuals with mild cognitive impairment, Biol Psychiatry, 83, 447, 10.1016/j.biopsych.2017.02.007 · DOI · Paper page

Cited by

See all 108

Metadata

Authors
Leclerc, M., Bourassa, P., Tremblay, C., Caron, V., Sugère, C., Emond, V., Bennett, D. A., & Calon, F.
Venue
Brain
Published
2022-10-25
Volume
146
Issue
1
Pages
75-90
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W4307182538
Cited by
108
References
44
FWCI
11.55
Type
journal article
Language
en
Open access
hybrid
Funders
  • Canadian Institutes of Health Research
  • Fonds de recherche du Québec-Santé
  • Fondation du CHU de Québe
  • Alzheimer Society of Canada
  • Fonds d’Enseignement et de la Recherche
  • Laval University

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.